FindTrial
Sign In

Study to assess the efficacy of the drug Cabazitaxel in patients with Metastatic Colorectal Cancer.

Randomized phase II b study of Cabazitaxel in metastatic Colorectal Cancer resistant to standard treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-001218-32-ES
Enrollment
Unknown
Registered
2012-04-17
Start date
2012-06-14
Completion date
Unknown
Last updated
2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer resistant to standard treatment. MedDRA version: 14.1 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: Jevtana Product Name: Cabazitaxel Product Code: XRP6258 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Cabazitaxel CAS Number: 183133-96-2 Current Sponsor

Sponsors

Rafael López López
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 55 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 14

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Spain

Contacts

Public ContactGraciela Rodrigálvarez Agra

Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER)

grodrigalvarez@caiber.net0034918 222 421

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026